Keytruda Unmasks Hiding HIV, Wins EU Approval for Kidney Cancer

By PacConAdmin | January 27, 2022

Merck’s Keytruda (pembrolizumab) has made a couple of headlines this week, drawing attention as a potential weapon against latent HIV infections, and winning approval in Europe as a kidney cancer monotherapy.
Source: Drug Industry Daily

Posted in Drug Industry Daily